Clinical Trials Logo

Herpes Genitalis clinical trials

View clinical trials related to Herpes Genitalis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06385327 Not yet recruiting - Clinical trials for Recurrent Genital Herpes Simplex Type 2

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes

Start date: May 2024
Phase: Phase 1
Study type: Interventional

This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-5366 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-5366 in Part B in participants seropositive for Herpes Simplex Virus Type 2 (HSV-2) with recurrent genital herpes. Effect of food will also be evaluated in Part A.

NCT ID: NCT04979975 Not yet recruiting - Clinical trials for Recurrent Genital Herpes

Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes

Start date: December 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of repeat-dose UB-621 for the recurrent genital HSV-2 infection To evaluate the safety and tolerance of repeat-dose UB-621 for the recurrent HSV-2 infection To evaluate the pharmacokinetics of repeat-dose UB-621 in RGH patients

NCT ID: NCT04714060 Not yet recruiting - Clinical trials for Recurrent Genital Herpes

UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals

Start date: October 1, 2023
Phase: Phase 2
Study type: Interventional

A randomized, single-blind, dose-selected phase II trial to evaluate the safety, efficacy and PK of UB-621 in adults with recurrent genital HSV-2 infection

NCT ID: NCT03595995 Not yet recruiting - Genital Herpes Clinical Trials

A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of two dose levels of UB-621 administration in reducing the HSV-2 genital shedding rate in patients with recurrent genital HSV-2 infection.